Randy Osborne

Atlanta

Staff Writer at BioWorld

staff writer at BioWorld Today

Featured in: Favicon

bioworld.com Favicon

medium.com

Articles

‘Complement’-ary approaches? FcRn holds ground in myasthenia gravis

3 days ago | bioworld.com | Randy Osborne

Many US tariffs paused, pharma warned, EU put on noticeThe on-again, off-again U.S. tariffs are off again, at least for now, for more than 75 countries that have reached out to the Trump administration to negotiate...
Post-Pfizer dropout, Lilly Achieves GLP-1 win in phase III

1 week ago | bioworld.com | Randy Osborne

Post-Pfizer dropout, Lilly Achieves GLP-1 win in phase IIIDays after Pfizer Inc. pulled the plug on its oral GLP-1 candidate danuglipron, Eli Lilly and Co. aired positive top-line data from the phase III trial called Achieve-1 testing orforglipron vs. placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. BioWorld Clinical Diabetes Endocrine/metabolic Small molecule U.S.
Ironwood: FDA nay on PK means another apraglutide study

1 week ago | bioworld.com | Randy Osborne

Home » Ironwood: FDA nay on PK means another apraglutide study BioWorld briefs for April 14, 2025. BioWorld MedTech briefs for April 14, 2025. Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans.... At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...
Spevigo so-so, innovator takes another Turn at IL-36 in eczema

1 week ago | bioworld.com | Randy Osborne

Spevigo so-so, innovator takes another Turn at IL-36 in eczemaWith a promising IL-36 inhibitor for atopic dermatitis (AD, or eczema) at the phase II stage, Turn Therapeutics Inc. has gained $75 million in post-public commitments and meanwhile is pursuing a grassroots strategy to keep the coffers in balance. BioWorld Analysis and data insight Clinical Dermatologic U.S.
IL-2 ADding contenders in eczema strategy

2 weeks ago | bioworld.com | Randy Osborne

IL-2 ADding contenders in eczema strategy The sparsity of mid-to-late stage prospects in atopic dermatitis (AD, or eczema) – which has proved an especially challenging indication – plus some newsmaking fizzles in the space have caused developers to probe new targets with particular intensity. Most popular approaches thus far involve IL-4, IL-13, thymic stromal lymphopoietin and JAK.
Neurosense phase II combo to hail new Paradigm in ALS?

2 weeks ago | bioworld.com | Randy Osborne

Neurosense phase II combo to hail new Paradigm in ALS? As developers continue to search for better amyotrophic lateral sclerosis (ALS) therapies, Neurosense Therapeutics Ltd. turned up some hopeful findings from its phase IIb Paradigm trial with PrimeC.
Cartesian math works out nicely in phase IIb MG trial

2 weeks ago | bioworld.com | Randy Osborne

Cartesian math works out nicely in phase IIb MG trialCartesian Therapeutics Inc. followed up December’s phase IIb data with more good news regarding Descartes-08, offering 12-month efficacy and safety results that whetted Wall Street’s appetite for the phase III Aurora effort ahead. BioWorld Clinical Immune Musculoskeletal CAR T Cell therapy U.S.
Easier row to HO with Imcivree as Rhythm phase III grooves

2 weeks ago | bioworld.com | Randy Osborne

Easier row to HO with Imcivree as Rhythm phase III groovesRhythm Pharmaceuticals Inc.’s sales with Imcivree (setmelanotide) in weight management could exceed $1 billion by 2028 if hypothalamic obesity (HO) is added to the label of the drug, Oppenheimer analyst Leland Gershell said in a report. Boston-based Rhythm rolled out positive top-line data from the pivotal phase III study called Transcend with the melanocortin-4 receptor agonist in HO.
Crescent moon shot to scale the Summit in VEGFxPD-1

2 weeks ago | bioworld.com | Randy Osborne

Crescent moon shot to scale the Summit in VEGFxPD-1Last October, having chalked another trial failure with E-selectin antagonist uproleselan, Glycomimetics Inc. made known its acquisition plan for privately held, solid tumor-focused Crescent Biopharma Inc. – backed by $200 million from a syndicate of investors who liked the odds of success with CR-001, a preclinical VEGFxPD-1 bispecific antibody. BioWorld Analysis and data insight Cancer Bispecific antibody
Reproxalap rapped again in DED; second Aldeyra CRL

3 weeks ago | bioworld.com | Randy Osborne

Reproxalap rapped again in DED; second Aldeyra CRLAldeyra Therapeutics Inc. is hoping that research already underway will satisfy the U.S. FDA, which delivered to the company another complete response letter (CRL) related to the NDA for reproxalap in dry eye disease (DED). BioWorld Regulatory Ocular Small molecule U.S. FDA